[English] 日本語
Yorodumi- EMDB-40646: CryoEM structure of a therapeutic antibody (favezelimab) bound to... -
+Open data
-Basic information
Entry | Database: EMDB / ID: EMD-40646 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Title | CryoEM structure of a therapeutic antibody (favezelimab) bound to human LAG3 | |||||||||
Map data | ||||||||||
Sample |
| |||||||||
Keywords | Lymphocyte activation gene 3 protein / favezelimab-LAG3 complex / cryoEM / Single particle reconstruction. / IMMUNOSUPPRESSANT | |||||||||
Function / homology | Function and homology information plasmacytoid dendritic cell activation / negative regulation of regulatory T cell differentiation / positive regulation of natural killer cell mediated cytotoxicity / MHC class II protein binding / natural killer cell mediated cytotoxicity / negative regulation of interleukin-2 production / regulation of immune response / MHC class II antigen presentation / antigen binding / T cell activation ...plasmacytoid dendritic cell activation / negative regulation of regulatory T cell differentiation / positive regulation of natural killer cell mediated cytotoxicity / MHC class II protein binding / natural killer cell mediated cytotoxicity / negative regulation of interleukin-2 production / regulation of immune response / MHC class II antigen presentation / antigen binding / T cell activation / transmembrane signaling receptor activity / adaptive immune response / cell surface receptor signaling pathway / external side of plasma membrane / extracellular region / plasma membrane Similarity search - Function | |||||||||
Biological species | Homo sapiens (human) / Mus musculus (house mouse) | |||||||||
Method | single particle reconstruction / cryo EM / Resolution: 3.61 Å | |||||||||
Authors | Mishra AK / Shahid S / Karade SS / Mariuzza RA | |||||||||
Funding support | United States, 1 items
| |||||||||
Citation | Journal: Structure / Year: 2023 Title: CryoEM structure of a therapeutic antibody (favezelimab) bound to human LAG3 determined using a bivalent Fab as fiducial marker. Authors: Arjun K Mishra / Salman Shahid / Sharanbasappa S Karade / Pragati Agnihotri / Alexander Kolesnikov / S Saif Hasan / Roy A Mariuzza / Abstract: Lymphocyte activation gene 3 protein (LAG3) is an inhibitory receptor that is upregulated on exhausted T cells in tumors. LAG3 is a major target for cancer immunotherapy with many anti-LAG3 ...Lymphocyte activation gene 3 protein (LAG3) is an inhibitory receptor that is upregulated on exhausted T cells in tumors. LAG3 is a major target for cancer immunotherapy with many anti-LAG3 antibodies in clinical trials. However, there is no structural information on the epitopes recognized by these antibodies. We determined the single-particle cryoEM structure of a therapeutic antibody (favezelimab) bound to LAG3 to 3.5 Å resolution, revealing that favezelimab targets the LAG3-binding site for MHC class II, its canonical ligand. The small size of the complex between the conventional (monovalent) Fab of favezelimab and LAG3 (∼100 kDa) presented a challenge for cryoEM. Accordingly, we engineered a bivalent version of Fab favezelimab that doubled the size of the Fab-LAG3 complex and conferred a highly identifiable shape to the complex that facilitated particle selection and orientation for image processing. This study establishes bivalent Fabs as new fiducial markers for cryoEM analysis of small proteins. | |||||||||
History |
|
-Structure visualization
Supplemental images |
---|
-Downloads & links
-EMDB archive
Map data | emd_40646.map.gz | 118 MB | EMDB map data format | |
---|---|---|---|---|
Header (meta data) | emd-40646-v30.xml emd-40646.xml | 17.6 KB 17.6 KB | Display Display | EMDB header |
Images | emd_40646.png | 152.9 KB | ||
Filedesc metadata | emd-40646.cif.gz | 6.3 KB | ||
Others | emd_40646_half_map_1.map.gz emd_40646_half_map_2.map.gz | 116.2 MB 116.2 MB | ||
Archive directory | http://ftp.pdbj.org/pub/emdb/structures/EMD-40646 ftp://ftp.pdbj.org/pub/emdb/structures/EMD-40646 | HTTPS FTP |
-Validation report
Summary document | emd_40646_validation.pdf.gz | 834.1 KB | Display | EMDB validaton report |
---|---|---|---|---|
Full document | emd_40646_full_validation.pdf.gz | 833.7 KB | Display | |
Data in XML | emd_40646_validation.xml.gz | 13.9 KB | Display | |
Data in CIF | emd_40646_validation.cif.gz | 16.4 KB | Display | |
Arichive directory | https://ftp.pdbj.org/pub/emdb/validation_reports/EMD-40646 ftp://ftp.pdbj.org/pub/emdb/validation_reports/EMD-40646 | HTTPS FTP |
-Related structure data
Related structure data | 8so3MC 6wkmC 8fwhC 8sr0C M: atomic model generated by this map C: citing same article (ref.) |
---|---|
Similar structure data | Similarity search - Function & homologyF&H Search |
-Links
EMDB pages | EMDB (EBI/PDBe) / EMDataResource |
---|---|
Related items in Molecule of the Month |
-Map
File | Download / File: emd_40646.map.gz / Format: CCP4 / Size: 125 MB / Type: IMAGE STORED AS FLOATING POINT NUMBER (4 BYTES) | ||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Projections & slices | Image control
Images are generated by Spider. | ||||||||||||||||||||||||||||||||||||
Voxel size | X=Y=Z: 1.12 Å | ||||||||||||||||||||||||||||||||||||
Density |
| ||||||||||||||||||||||||||||||||||||
Symmetry | Space group: 1 | ||||||||||||||||||||||||||||||||||||
Details | EMDB XML:
|
-Supplemental data
-Half map: #2
File | emd_40646_half_map_1.map | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Projections & Slices |
| ||||||||||||
Density Histograms |
-Half map: #1
File | emd_40646_half_map_2.map | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Projections & Slices |
| ||||||||||||
Density Histograms |
-Sample components
-Entire : therapeutic antibody (favezelimab) bound to human LAG3
Entire | Name: therapeutic antibody (favezelimab) bound to human LAG3 |
---|---|
Components |
|
-Supramolecule #1: therapeutic antibody (favezelimab) bound to human LAG3
Supramolecule | Name: therapeutic antibody (favezelimab) bound to human LAG3 type: complex / ID: 1 / Parent: 0 / Macromolecule list: #1-#3 |
---|---|
Source (natural) | Organism: Homo sapiens (human) |
-Macromolecule #1: Lymphocyte activation gene 3 protein
Macromolecule | Name: Lymphocyte activation gene 3 protein / type: protein_or_peptide / ID: 1 / Number of copies: 2 / Enantiomer: LEVO |
---|---|
Source (natural) | Organism: Homo sapiens (human) |
Molecular weight | Theoretical: 57.50827 KDa |
Recombinant expression | Organism: Homo sapiens (human) |
Sequence | String: MWEAQFLGLL FLQPLWVAPV KPLQPGAEVP VVWAQEGAPA QLPCSPTIPL QDLSLLRRAG VTWQHQPDSG PPAAAPGHPL APGPHPAAP SSWGPRPRRY TVLSVGPGGL RSGRLPLQPR VQLDERGRQR GDFSLWLRPA RRADAGEYRA AVHLRDRALS C RLRLRLGQ ...String: MWEAQFLGLL FLQPLWVAPV KPLQPGAEVP VVWAQEGAPA QLPCSPTIPL QDLSLLRRAG VTWQHQPDSG PPAAAPGHPL APGPHPAAP SSWGPRPRRY TVLSVGPGGL RSGRLPLQPR VQLDERGRQR GDFSLWLRPA RRADAGEYRA AVHLRDRALS C RLRLRLGQ ASMTASPPGS LRASDWVILN CSFSRPDRPA SVHWFRNRGQ GRVPVRESPH HHLAESFLFL PQVSPMDSGP WG CILTYRD GFNVSIMYNL TVLGLEPPTP LTVYAGAGSR VGLPCRLPAG VGTRSFLTAK WTPPGGGPDL LVTGDNGDFT LRL EDVSQA QAGTYTCHIH LQEQQLNATV TLAIITVTPK SFGSPGSLGK LLCEVTPVSG QERFVWSSLD TPSQRSFSGP WLEA QEAQL LSQPWQCQLY QGERLLGAAV YFTELSSPGA QRSGRAPGAL PAGHLLLFLI LGVLSLLLLV TGAFGFHLWR RQWRP RRFS ALEQGIHPPQ AQSKIEELEQ EPEPEPEPEP EPEPEPEPEQ L UniProtKB: Lymphocyte activation gene 3 protein |
-Macromolecule #2: favezelimab Fab heavy chain
Macromolecule | Name: favezelimab Fab heavy chain / type: protein_or_peptide / ID: 2 / Number of copies: 2 / Enantiomer: LEVO |
---|---|
Source (natural) | Organism: Mus musculus (house mouse) |
Molecular weight | Theoretical: 27.245727 KDa |
Recombinant expression | Organism: Homo sapiens (human) |
Sequence | String: MGWTWIFLFF LSGTAGVLSE VLLLQSGPEL VKPGTSVKIP CKASGYTFTD YNVDWVKQRH GKGLEWIGDI NPNNGGTIYS QKFKGKATL TVDKSSSTAF MELRSLTSED TAVYFCARNY RWFGAMDHWG QGTSVTVSST KGPSVFPLAP SSKSTSGGTA A LGCLVKDY ...String: MGWTWIFLFF LSGTAGVLSE VLLLQSGPEL VKPGTSVKIP CKASGYTFTD YNVDWVKQRH GKGLEWIGDI NPNNGGTIYS QKFKGKATL TVDKSSSTAF MELRSLTSED TAVYFCARNY RWFGAMDHWG QGTSVTVSST KGPSVFPLAP SSKSTSGGTA A LGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKRVEPKS CD KTAGWSH PQFEK |
-Macromolecule #3: favezelimab Fab light chain
Macromolecule | Name: favezelimab Fab light chain / type: protein_or_peptide / ID: 3 / Number of copies: 2 / Enantiomer: LEVO |
---|---|
Source (natural) | Organism: Mus musculus (house mouse) |
Molecular weight | Theoretical: 25.915627 KDa |
Recombinant expression | Organism: Homo sapiens (human) |
Sequence | String: METDTILLWV LLLWVPGSTG DIVLTQSPAS LAVSPGQRAT ISCKASQSLD YEGDSDMNWY QQKPGQPPRL LISGASNLES GIPARFSGS GSGTDFTVNI HPVEEEDAAT YYCQQSTEDP RTFGGGTKLE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL L NNFYPREA ...String: METDTILLWV LLLWVPGSTG DIVLTQSPAS LAVSPGQRAT ISCKASQSLD YEGDSDMNWY QQKPGQPPRL LISGASNLES GIPARFSGS GSGTDFTVNI HPVEEEDAAT YYCQQSTEDP RTFGGGTKLE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL L NNFYPREA KYQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC EVTHQGLSSP VTKSFNRGEC |
-Macromolecule #4: 2-acetamido-2-deoxy-beta-D-glucopyranose
Macromolecule | Name: 2-acetamido-2-deoxy-beta-D-glucopyranose / type: ligand / ID: 4 / Number of copies: 4 / Formula: NAG |
---|---|
Molecular weight | Theoretical: 221.208 Da |
Chemical component information | ChemComp-NAG: |
-Experimental details
-Structure determination
Method | cryo EM |
---|---|
Processing | single particle reconstruction |
Aggregation state | particle |
-Sample preparation
Buffer | pH: 8 |
---|---|
Grid | Material: COPPER |
Vitrification | Cryogen name: ETHANE / Chamber humidity: 100 % / Chamber temperature: 277 K / Instrument: FEI VITROBOT MARK IV |
-Electron microscopy
Microscope | FEI TITAN KRIOS |
---|---|
Image recording | Film or detector model: GATAN K3 (6k x 4k) / Number grids imaged: 1 / Number real images: 9508 / Average exposure time: 3.2 sec. / Average electron dose: 50.0 e/Å2 |
Electron beam | Acceleration voltage: 300 kV / Electron source: FIELD EMISSION GUN |
Electron optics | Illumination mode: OTHER / Imaging mode: BRIGHT FIELD / Cs: 2.7 mm / Nominal defocus max: 2.5 µm / Nominal defocus min: 1.0 µm / Nominal magnification: 81000 |
Sample stage | Cooling holder cryogen: NITROGEN |
Experimental equipment | Model: Titan Krios / Image courtesy: FEI Company |
-Image processing
Startup model | Type of model: NONE |
---|---|
Final reconstruction | Resolution.type: BY AUTHOR / Resolution: 3.61 Å / Resolution method: FSC 0.143 CUT-OFF / Number images used: 171144 |
Initial angle assignment | Type: OTHER |
Final angle assignment | Type: OTHER |